VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment;VEGF a zwyrodnienie plamki zwiazane z wiekiem. Cześć II. Inhibitory VEGF w leczeniu zwyrodnienia plamki zwiazanego z wiekiem

Klinika Oczna

Volumn 109, Issue 1-3, 2007, Pages 97-100

  Wylegała, Edward ^a,b,c   Teper, Sławomir Jan ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Z Oddzialu Okulistycznego Okregowego Szpitala Kolejowego w Katowicach   (Poland)

^c Okregowy Szpital Kolejowy   (Poland)

Author keywords

AMD; VEGF; Vegf inhibitors

Indexed keywords

EID: 34447521452     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V.: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci., 2005 Feb, 46(2), 726-733.
2. Sakamoto K.M.: Semaxanib (SUGEN). IDrugs., 2001 Sep, 4(9), 1061-1067.
3. Kinose F., Roscilli G., Lamartina S., Anderson K.D., Bonelli F., Spence S.G., Ciliberto G., Vogt T.F., Holder D.J., Toniatti C., Thut C.J.: Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol. Vis., 2005 May 27, 11, 366-373.
4. Tolentino M.J., Brucker A.J., Fosnot J., et al.: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina, 2004, 24, 132-138.
5. Gragoudas E.S., Adamis A.P., Cunningham E.T. Jr., Feinsod M., Guyer D.R.: VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med., 2004 Dec 30, 351(27), 2805-2816.
6. Gonzales C.R.: VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratoryanalysis. Retina, 2005 Oct-Nov, 25(7), 815-827.
7. Herbert Hurwitz, M.D., Louis Fehrenbacher, M.D., William Novotny, M.D., Thomas Cartwright, M.D., John Hainsworth, M.D., William Heim, M.D., Jordan Berlin, M.D., Ari Baron, M.D., Susan Griffing, B.S., Eric Holmgren, Ph.D., Napoleone Ferrara, M.D., Gwen Fyfe, M.D., Beth Rogers, B.S., Robert Ross, M.D., and Fairooz Kabbinavar, M.D. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004 Jun 3, 350(23), 2335-2342.
8. Shahar J., Avery R.L., Heilweil G., Barak A., Zemel E., Lewis G.P., Johnson P.T., Fisher S.K., Perlman I., Loewenstein A.: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina, 2006 Mar, 26(3), 262-269.
9. Rosenfeld P.J., Moshfeghi A.A., Puliafito C.A.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging, 2005 Jul-Aug, 36(4), 331-335.
10. Spaide R.F., Laud K., Fine H.F., Klancnik J.M. Jr., Meyerle C.B., Yannuzzi L.A., Sorenson J., Slakter J., Fisher Y.L., Cooney M.J.: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina, 2006 Apr, 26(4), 383-390.
11. Maturi R.K., Bleau L.A., Wilson D.L.: Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina, 2006 Mar, 26(3), 270-274.
12. Rosenfeld P.J., Heier J.S., Hantsbarger G., Shams N.: Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology, 2006 Apr, 113(4), 632. e1.
13. Heier J.S., Antoszyk A.N., Pavan P.R., Leff S.R., Rosenfeld P.J., Ciulla T.A., Dreyer R.F., Gentile R.C., Sy J.P., Hantsbarger G., Shams N.: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology, 2006, Apr, 113(4), 642. e1-4. Epub 2006 Feb14.
14. Husain D., Kim I., Gauthier D., Lane A.M., Tsilimbaris M.K., Ezra E., Connolly E.J., Michaud N., Gragoudas E.S., O'Neill C.A., Beyer J.C., Miller J.W.: Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch. Ophthalmol., 2005 Apr, 123(4), 509-516.
15. Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V.: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Incest. Ophthalmol. Vis. Sci. 2005 Feb, 46(2), 726-733.
16. Kaiser P.: Anchor data. Program of Macula 2006; January 13-14, 2006, New York, NY.
17. Miller J., Chung C.Y., Kim R.Y., MARINA Study Group: Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting; July 16-20, 2005, Montreal, Canada.
18. Glusker P., Recht L., Lane B.: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med., 2006 Mar 2, 354(9), 980-2, discussion 980-982.
19. Dhalla M.S., Blinder K.J., Tewari A., Hariprasad S.M., Apte R.S.: Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am. J. Ophthalmol., 2006 Apr, 141(4), 752-754.
20. Kim I.K., Husain D., Michaud N., Connolly E., Lane A.M., Durrani K., Hafezi-Moghadam A., Gragoudas E.S., O'Neill C.A., Beyer J.C., Miller J.W.: Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest. Ophthalmol. Vis. Sci., 2006 Jan, 47(1), 357-363.